PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Both yoy net incomes decline, with CRVO at -12.37%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.30%
Some D&A expansion while CRVO is negative at -47.14%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth while CRVO is negative at -2.52%. John Neff would see competitor possibly controlling share issuance more tightly.
170.16%
Less working capital growth vs. CRVO's 477.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Lower 'other working capital' growth vs. CRVO's 3360.40%. David Dodd would see fewer unexpected short-term demands on cash.
169.42%
Growth of 169.42% while CRVO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-4.39%
Negative yoy CFO while CRVO is 17.52%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
94.15%
CapEx growth of 94.15% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.